Ozempic
Compounding scandal hit pharmacists’ reputations
Dodgy Ozempic sold online by a company linked to a Sydney-based pharmacist has damaged the profession’s trusted status Revelations that products sold through online pharmacies as compounded semaglutide have been …
Pharmacists warned to be on lookout for fake ‘Ozempic’ pens
The counterfeit pens appear to be relabelled insulin pens, with one life-threatening adverse event already reported in Australia The TGA has issued a safety alert over counterfeit Ozempic-labelled pens entering …
Limited PBS access, shortages may impact add-on therapy
Prevalence of add-on therapy in people with type 2 diabetes is “low” and should be increased to save lives, PBS records analysis finds More Australians with type 2 diabetes need …
Medicines shortages – ‘this is not okay’
Government urged to talk to rural pharmacists about the persistent issues impacting Australia’s medicines supply chain “No other country has had the same issues” as Australia when it comes to …
Petition seeks rethink of GLP-1 RAs compounding ban
Politicians are being urged to reconsider the decision to ban the compounding of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) until supply issues ease Patients are calling for the government’s decision …
Wegovy’s arrival provides Ozempic alternative for weight management
Supplies of Ozempic (semaglutide) should be prioritised for type 2 diabetes patients the TGA says, as sponsor Novo Nordisk, launches its Wegovy brand for weight loss Pharmacists and prescribers are …
Ozempic shortages to continue: Butler
Novo Nordisk “simply doesn’t have the factories” to meet growing demand for Ozempic, Health Minister says Shortages of Novo Nordisk’s diabetes medication, Ozempic (semaglutide) are likely to continue into 2025, …
Caution with click method for semaglutide pen
PDL has become aware of a number of adverse events and health consequences from the popularised method of Ozempic (semaglutide) administration known as “counting clicks” Understanding the click method …
Diabetes shortages targeted in report
Shortages of existing diabetes medicines are likely to continue through 2024 and beyond, warns a new report which recommends strengthening the supply chain The 2024 State of the Nation report from Diabetes …
Ozempic compounding ban no ‘knee-jerk’ reaction
Department defends recommendation to ban the compounding of semaglutide and tirepatide medications Moves to prohibit pharmacists from compounding replicas of Ozempic (semaglutide) and Mounjaro (tirepatide) were not a “knee-jerk response” …
Pharmacy fined over Ozempic advertising
Western Sydney pharmacy hit with a fine of more than $18,000 in relation to alleged unlawful advertising of Ozempic The Therapeutic Goods Administration (TGA) has issued an infringement notice of $18,780 …